Objectives:

  1. Discuss the rationale and current use of hypomethylating agents in acute myeloid leukemia
  2. Describe a big-data based evaluation of current hypomethylating agent use in AML
  3. Outline a trial of guadecitabine in previously untreated TP53-mutant and adverse-risk AML

Objectives:

  1. Immune related adverse events (irAEs) and quick pathophysiology
  2. Current recommendations on management of irAEs
  3. Predicting onset and severity of irAEs
  4. Collaboration between Oncology and Rheumatology for future research
Session date: 
Monday, October 9, 2017 - 12:00pm to 1:00pm
Speaker Name: 
Andrew Hantel, MD 2nd Year Fellow - Section of Hematology/Oncology and Pankti Reid, MD, MPH 2nd Year Fellow – Department of Rheumatology; 1st Year Fellow – Department of Clinical Pharmacology & Pharmacogenomics - University of Chicago Medicine
Location: 
UCMC
5841 South Maryland Avenue
MC2115, Conference Room E-215
Chicago, IL 60637
United States
  • 1.00 AMA PRA Category 1 Credit™
  • 1.00 Participation

Please login or create an account to proceed.